RxDoctor Payments Data

Kimberly Cline

Family · Conover, NCNPI 1265579833

Payments from drug & device makers

$8,774in general payments, 2019–2025

Across 431 payments — averaging $20.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • AstraZeneca$1K
  • Novo Nordisk$1K
  • GSK$617
  • Bayer$518
  • Lilly USA, LLC$492
  • plus $3K from 37 others

What the payments were for

  • Food & beverage$8,72899%
  • Education$461%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,774 in reported general payments places this provider in the 95th percentile of 4,522 family providers in North Carolina.

See all family providers in North Carolina

Medicare billing

Part B allowed, 2024
$28,796
Medicare patients
97
Services billed
613

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide125$148,495
FarxigaDapagliflozin Propanediol100$77,657
MounjaroTirzepatide48$66,092
EliquisApixaban80$63,392
JardianceEmpagliflozin62$55,969
RybelsusSemaglutide33$45,518
TrulicityDulaglutide33$36,054
Trelegy ElliptaFluticasone/Umeclidin/Vilanter35$35,730
Repatha SureclickEvolocumab32$24,042
KerendiaFinerenone29$22,334
Breztri AerosphereBudesonide/Glycopyr/Formoterol25$17,325
MyrbetriqMirabegron34$16,957
Soliqua 100-33Insulin Glargine/Lixisenatide18$15,133
Tresiba Flextouch U-100Insulin Degludec21$11,447
XareltoRivaroxaban14$10,777

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,170$194,013158 claims
Lilly USA, LLCMounjaro, Trulicity$492$102,14681 claims
AstraZenecaFarxiga, Breztri Aerosphere$1,254$94,983125 claims
PfizerEliquis$305$63,39280 claims
Boehringer IngelheimJardiance$355$55,96962 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$617$55,64874 claims
Astellas Pharma US IncMyrbetriq, Veozah$96$27,42551 claims
BayerKerendia$518$22,33429 claims
MerckJanuvia, Belsomra$17$15,39722 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$95$15,13318 claims
Sumitomo Pharma America, Inc.Gemtesa$55$10,03112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,522 family providers in North Carolina.

Other family in Conover

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →